Organization | Fibrolamellar Cancer Foundation

Fibrolamellar Cancer Foundation Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial

2016

NCT02702960

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 2 Trials (9)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

autologous bone marrow (1 trial)

cyclophosphamide (cytoxan) (1 trial)

fludarabine (fludara) (1 trial)

mesna (mesnex) (1 trial)

mycophenolate (myfortic) (1 trial)

prednisone (meticorten) (1 trial)

sargramostim (leukine) (1 trial)

tacrolimus (prograf) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 1
# of Trial APIs: 9